Monument Therapeutics partners with FNIH for schizophrenia drug trial

CAMBRIDGE, UK - Monument Therapeutics has partnered with the Foundation for the National Institutes of Health (FNIH) to evaluate MT1988, a novel treatment for cognitive impairment associated with schizophrenia, in a proof of principle clinical trial.

The trial will be conducted as part of the FNIH-managed Accelerating Medicines Partnership Schizophrenia program, a public-private collaboration that has secured $44 million in investment commitments to date. The initiative includes the National Institutes of Health, pharmaceutical companies, and nonprofit organizations.

Schizophrenia ranks among the top 15 causes of disability worldwide, with symptoms including hallucinations, delusions, and cognitive impairments. Many individuals show early signs during a "clinical high risk" phase, which currently lacks effective treatment options.

Cambridge Cognition Holdings (LON:COGC) plc (AIM:COG), which holds a 20% stake in Monument Therapeutics valued at £1.8 million, reported that its proprietary digital cognitive assessment technologies supported the early development of MT1988. The company also retains future royalty rights in Monument following its spin-out in 2021.

"Monument’s continued progress into patient trials is a significant step in developing precision treatments for brain health," said Rob Baker, Joint Managing Director and Chief Operating Officer at Cambridge Cognition, according to the press release.

Monument Therapeutics, headquartered in Manchester, UK, applies a strategy that leverages digital assessments of cognition to select patients suitable for treatment with new drugs.

The AMP (OTC:AMLTF) Schizophrenia program aims to accelerate the development of more effective treatments for schizophrenia and related mental health conditions through collaborative research efforts.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.